Effect Modifiers and Risk Factors of Intraocular Inflammation Following Brolucizumab: A Systematic Review and
Hashem Abu Serhan1, Amr K Hassan2, Mohamed Rifai3
1Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar.
Current Eye Research
|September 25, 2024
Summary
Intraocular inflammation (IOI) occurred in 6% of patients treated with brolucizumab, particularly in the elderly and females. This systematic review identifies risk factors to optimize brolucizumab patient care.
Area of Science:
- Ophthalmology
- Medical Research
Background:
- Brolucizumab is a treatment for retinal and choroidal vascular diseases.
- Intraocular inflammation (IOI) is a known complication associated with brolucizumab therapy.
Purpose of the Study:
- To identify risk factors and effect modifiers for IOI following brolucizumab injection.
- To provide insights for optimizing patient care and treatment strategies.
Main Methods:
- Systematic review of 33 papers including 3527 eyes.
- Searched six electronic databases for studies reporting IOI after brolucizumab.
- Data analyzed using mean difference with 95% confidence intervals; risk of bias assessed.
Main Results:
- The most common complication was IOI, occurring in 196 eyes (6%).
- IOI was more prevalent in elderly patients (76.3 years), females (66%), and after the second injection.
- Significant improvements were observed in subretinal fluid, intraretinal fluid, pigment epithelial detachment, and visual acuity post-intervention.
Conclusions:
- This review offers valuable insights into risk factors for IOI with brolucizumab, aiding clinical decision-making.
- Further prospective, long-term studies are recommended to fully understand brolucizumab's safety profile and refine its use.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
406
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
406
01:25Glaucoma: Overview
528
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
528
01:28Angle Closure Glaucoma: Treatment
451
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
451